You are here: Industry Insights > NICE

News List

Kidney cancer charity slams NICE rejection of Keytruda/Inlyta pharmatimes
August 28, 2020
MSD’s Keytruda (pembrolizumab) in combination with Pfizer's Inlyta (axitinib) has been turned down by NICE as first-line treatment for patients with advanced renal cell carcinoma (RCC).
NICE publishes guidance on Astellas' Xospata pharmatimes
August 18, 2020
The National Institute for Health and Care Excellence has now published final guidance backing NHS use of Astellas' Xospata as monotherapy for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia (AML).
NICE updates guidance on chronic pain treatments pharmatimes
August 07, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance which details how some commonly used drug treatments for chronic primary pain have little to no effect.
NICE does not recommend chlormethine gel to treat T-cell lymphoma in draft guidance europeanpharmaceuticalreview
August 07, 2020
NICE has issued draft guidance that does not recommend chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
Commonly used treatments for chronic pain do not work, says NICE europeanpharmaceuticalreview
August 06, 2020
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.
NICE recommends avelumab and axitinib to treat renal cell carcinoma europeanpharmaceuticalreview
August 03, 2020
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
NICE backs Bavencio combo for kidney cancer pharmatimes
July 31, 2020
The National Institute for Health and Care Excellence (NICE) has recommended NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) in combination with axitinib as a first-line treatment for kidney cancer.
NICE rejects NHS funding for Kyowa Kirin's Poteligeo pharmatimes
July 31, 2020
NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis fungoides or Sézary syndrome for adults who have had at least one previous systemic treatment.
NICE backing for Astella's Xospata pharmatimes
July 20, 2020
NICE has recommended use of Astellas' Xospata (gilteritinib) for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia (AML).
NICE backing for Takeda's Adcetris for rare lymphoma pharmatimes
July 14, 2020
Takeda's Adcetris (brentuximab vedotin) has won the backing of the National Institute for Health and Care Excellence (NICE) as a treatment for untreated systemic anaplastic large cell lymphoma (sALCL), a rare type of lymphoma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page